Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer

W. D. Figg, N. Dawson, M. N. Middleman, O. Brawley, R. M. Lush, A. Senderowicz, S. H. Steinberg, S. H. Tompkins, A. Tompkins, E. Reed, O. Sartor

Research output: Contribution to journalArticlepeer-review

Abstract

The effect of aminoglutethimide administration on the flutamide withdrawal in a small population of hormone refractory prostate cancer patients who progressed after initial treatment with combined androgen blockade, suramin, and hydrocortisone is investigated. Patients involved in the study were determined to have progressive disease following treatment with leuprolide, flutamide, hydrocortisone, and suramin. The therapeutic efficacy of flutamide withdrawal with the initiation of aminoglutethimide was assessed with serial PSA measurements. An increase in the PSA normalization response rate was observed and was attributed to the fact that the patient all received flutamide initially as a component of complete androgen blockade therapy.

Original languageEnglish (US)
Pages (from-to)763-765
Number of pages3
JournalActa Oncologica
Volume35
Issue number6
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer'. Together they form a unique fingerprint.

Cite this